On 25 September 2026, LabCom DECIPHER (DEcoding Cancer resistance via Integrated PHarmacogenomics and Epigenetics Research) will host its first open scientific seminar at CIRM, Luminy Campus (Marseille). Born from a strategic partnership between the TAGC research unit (Inserm / Aix-Marseille University) and the biotechnology company Advanced BioDesign, DECIPHER focuses on cutting-edge pharmacogenomics and epigenetics to decode resistance mechanisms in cancer therapies and uncover novel therapeutic strategies, notably targeting aldehyde dehydrogenases (ALDH). This seminar offers a unique opportunity for researchers, clinicians, and industry partners to explore current projects, multi-omics tools, and clinical translation perspectives.
Detailed Programme:
- 09:00 – 09:45: Registration & Welcome Coffee at CIRM
- 09:45 – 10:00: Presentation of LabCom DECIPHER – Salvatore Spicuglia (TAGC)
- 10:00 – 10:15: Overview of the ANR LabCom Programme – ANR Representative
- 10:15 – 10:30: AMIDEX – ANR LabCom Co-funding Scheme – Vincent Audibert (Director, AMidex Foundation)*
- 10:30 – 10:45: Presentation of Advanced BioDesign – Ismaïl Ceylan (CEO, Advanced BioDesign)
- 10:45 – 11:15: Coffee Break
- 11:15 – 11:30: The ODISSEY Clinical Trial – Pr Régis Costello (PUPH Hôpital de la Conception, TAGC)
- 11:30 – 11:45: Targeting ALDHs in AML: from functional dependency to therapeutic vulnerability – Mileidys Perez-Alea
- 11:45 – 12:00: Integration of multi-omics data and genomic screens to identify novel therapeutic opportunities – Salvatore Spicuglia (TAGC)
- 12:00 – 13:00: Networking Cocktail at TAGC (TGML Room)
Practical Information:
- Location: CIRM Meeting Room, Luminy Campus, Marseille
- Registration: Admission is free, but prior registration is mandatory.
